Efficacy of Intranasal Fluticasone Nasal Spray Alone Versus Intranasal Fluticasone Combined with Oral Montelukast and Levocetirizine in Treatment of Allergic Rhinitis–A Randomized Control Trial.

Authors

  • Mohamed Afsal Y 1MS ENT – Post Graduate, S. N. Medical College & H. S. K. Hospital, Bagalkot, Karnataka, India
  • Chandrashekharayya S Hiremath MS ENT - Professor and Head of Department, S. N. Medical College & H. S. K. Hospital Bagalkot, Karnataka, India

Keywords:

Rhinits, Allergic, Fluticasone, Montelukast

Abstract

BACKGROUND: Allergic Rhinitis (AR) is characterized by an immunological response facilitated by IgE antibodies inside the nasal mucosa, which is initiated upon exposure to allergens present in the air. The illness under consideration is characterized by symptoms including the presence of watery nasal discharge, nasal congestion, sneezing, and nasal itching. It affects between 10 and 40 per cent of the global population, which affecting the quality of life of many persons. Hence, the requirement of a treatment targeted at delivering maximum symptom control and has minimum to nil adverse effects. AR symptoms impair cognitive function, which can be further exacerbated by the use of widely available first-generation antihistamines.

OBJECTIVES: To assess the improvement of nasal symptoms in both Fluticasone alone group and Fluticasone with Montelukast and levocetirizine group at the end of 1st month and 2nd month.

METHODS: Ethical approval was obtained from the Institutional Ethics Committee (IEC). A Randomized control study was done on 40 patients, aged above 15years who had Allergic rhinitis. Sample size estimation was done using OpenEPiSoftwareVersion2.3.1. Diagnosis was made based on Allergic Rhinitis and its Impact on Asthma (ARIA) criteria. Patients were randomized by simple randomization into two groups of 20 each. After proper history and physical examination of both nostril along with Absolute Eosinophil count was done. Group 1 received 2 puffs of Fluticasone furoate nasal spray (27.5mcg) in each nostril twice daily for 1 month, whereas Group 2 received both Fluticasone furoate nasal spray twice daily with oral montelukast and levocetrizine for 1 month. Patients were assessed by Daily Rhinitis Diary Card. The symptoms were assessed during treatment, post treatment at 1st month and 2nd month. Statistical analysis was done using SPSS 19 software and appropriate statistical tests were applied. Inclusion Criteria: Patients aged between 18-60 years of age with Allergic rhinitis symptoms. Exclusion Criteria: Smokers, patients on oral steroids, patients with recent nasal surgeries, patients with nasal polyposis.

RESULTS: In this study, the results showed significant improvement in Day time symptom scores for both group after 1 month. Better symptom relief seen in fluticasone with montelukast group. The combination group showed better symptom free interval after stopping the treatment. In case of night time symptom score, there were difference but it was found to be statistically insignificant (p>0.001).

CONCLUSION: As per the study, Fluticasone combined with montelukast and levocetrizine was effective in reducing daytime and night time symptoms as compared to fluticasone alone.

Metrics

Metrics Loading ...

References

Dhingra PL, Dhingra S. Diseases of Ear, Nose & Throat and Head & Neck Surgery-E-Book. Elsevier Health Sciences; 2021 Sep 15:194.

Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, Melén E, Palomares O, Scadding GK, Togias A, Toppila-Salmi S. Allergic rhinitis. Nature Reviews Disease Primers. 2020 Dec 3;6(1):95.

Goh BS, Ismail MI, Husain S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study. J Laryngol Otol. 2014 Mar;128(3):242-8.

Martin BG, Andrews CP, van Bavel JH, Hampel FC, Klein KC, Prillaman BA, et al. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol. 2006 Jun;96(6):851-7.

Downloads

Published

2025-01-01

How to Cite

Mohamed Afsal Y, & Hiremath, C. S. (2025). Efficacy of Intranasal Fluticasone Nasal Spray Alone Versus Intranasal Fluticasone Combined with Oral Montelukast and Levocetirizine in Treatment of Allergic Rhinitis–A Randomized Control Trial. International Journal of Medical Students, 12, S345. Retrieved from https://ijms.pitt.edu/IJMS/article/view/2918

Issue

Vol 12. (2024): Supplement 1

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2024 Mohamed Afsal Y

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org